Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Vaccine Production in Plants Nets Scientist Innovator of the Year 2012

Published: Friday, March 30, 2012
Last Updated: Thursday, March 29, 2012
Bookmark and Share
Innovation could allow quicker vaccine development to combat pandemics.

Professor George Lomonossoff has been named BBSRC Innovator of the Year 2012 for his work with Dr Frank Sainsbury, to develop a system for producing vaccines and pharmaceutical proteins rapidly in plants.

The system could allow vaccines to be produced much more rapidly for emergency vaccination programmes in the face of disease pandemics.

Professor Lomonossoff, of the John Innes Centre in Norwich, which receives strategic funding from BBSRC, and Dr Sainsbury, of Laval University in Canada, received their prize and trophy from Business Secretary, Vince Cable, who spoke at the final in London last night.

Dr Cable said: “I would like to congratulate the winners on their success. Their innovative ideas highlight the vital role that scientific knowledge plays in driving growth in important sectors like healthcare, food, and pharmaceuticals.

“The UK is a world leader in the biosciences and it is vital that we capitalize on this strength to deliver the maximum social and economic benefit. All of the finalists have gone to impressive lengths to ensure that the impacts of their research are felt well beyond the scientific community and this is truly worth celebrating.”

Professor Lomonossoff and Dr Sainsbury’s innovation enables proteins to be produced much more rapidly and at higher levels than has previously been possible in plants.

This is revolutionizing the use of plants as bioreactors and will help make plant-produced proteins a commercial reality.

The system has already been licensed to a number of potential partners in the commercial sector including the biopharmaceutical company Medicago.

Medicago are already using Professor Lomonossoff and Dr Sainsbury’s system as the principal production platform for a number of vaccines and therapeutic proteins currently in development.

Professor Lomonossoff expressed his delight at winning, saying: “You want to hope but you don’t dare. It’s a big surprise; rather like winning an Oscar.”

Professor Lomonossoff also thanked the many people who had helped to make the project a reality.

The judging panel gave the following comment of Professor Lomonosssoff’s innovation: “The panel were impressed by the innovators drive and passion, and speed with which the technology was moved forward. He had thought really hard about what the end customer wanted and was very realistic about the scope of the technology. The judging panel considered that the innovation had the potential to have much wider impact in the future.”

Professor Lomonossoff and Dr Sainsbury also won the prize for the Most Promising Innovator. Two other category prizes - Commercial Innovator and Social Innovator - were won by Professor Jim Murray of Cardiff University and his co-applicant Dr Laurence Tisi of Lumora Ltd, and Professor Russell Foster of the University of Oxford respectively.

Professor Russell Foster of the University of Oxford was awarded the Social Innovator prize for his work to revolutionist our understanding of the eye which has had impacts both in the clinic and further afield.

His findings are having a major impact across society helping, for example, with the design of new lighting systems and the use of natural light in buildings.

Professor Jim Murray of Cardiff University took the Commercial Innovator prize with Dr Laurence Tisi of Kumora Ltd, for their efforts in developing a system, called BART (Bioluminescent Assay in Real-Time), for detecting infectious organisms like bacteria and viruses that can be used almost anywhere. This could dramatically improve healthcare for patients in the developed and developing world.

The Biotechnology and Biological Sciences Research Council (BBSRC) Innovator of the Year Award is a competition designed to recognize and reward scientists who are ensuring that the UK's excellent bioscience research is translated into outcomes that positively affect economic growth and quality of life for everyone.

The award, now in its fourth year, was established with a view to encouraging researchers to consider the potential of their research and take the necessary steps to maximize the social and economic impact of the excellent work they do.

The nine finalists (see 'Notes to editors' section for details) were selected by an independent judging panel to compete in each of the three categories and for the overall prize.

Also speaking at the final was Jeremy Webb, Editor-in-Chief of New Scientist. Offering his congratulations, he said: “I don’t think I’ve come across a better collection of ideas in all my travels with the New Scientist over the past 20 years.”

Dr Celia Caulcott, Director of Innovation and Skills, BBSRC said: "This is the age of bioscience with techniques and technologies advancing at an exciting pace. These advances underpin so much that is so very important in our daily lives, such as food, health and fuel. The bioscience research community can make an enormous difference to mitigating the great challenges we face, enabling food security and life-long well-being, and helping to address climate change. Today's innovations highlight the impact of this potential and the enormous possibilities from bioscience."

Talking about the potential for innovation in Bioscience, Glyn Edwards, Chief Executive, UK BioIndustry Association, said: “The UK is a stunningly good place to do this. There has never been a better time for bioscience.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Way to Improve Antibiotic Production
A discovery has been made which could make it easier to scale up antibiotic production for commercialisation.
Tuesday, June 18, 2013
BBSRC is Major Partner in Europe-wide Synthetic Biology Funding
BBSRC is contributing €3M as a major partner in a new call for research projects in Synthetic Biology.
Tuesday, May 14, 2013
H7N9: A Novel Influenza Virus and it’s Control
Whilst the virus remains as one primarily circulating in birds, breaking this cycle of replication is the only effective response to its control.
Thursday, May 09, 2013
BBSRC Supports Call for Multi-Disciplinary Research Centres in Synthetic Biology
Up to six centres will be funded in two phases; three in this financial year and three next financial year.
Friday, May 03, 2013
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!